Dubai – AGBL Egypt announced the successful installation of a next generation sequencing system at the Ministry of Defense, Chemical Warfare Department in Cairo, Egypt. AGBL Egypt team provided the necessary technical training and support to the Chemical Warfare Department technicians.
Major Dr. Mohamed Gomaa Seadawy, The Commander of Biological Prevention and Control Department at the Ministry of Defense, Chemical Warfare Department said, “The project we worked on “Complete Genome Sequencing of SARS-CoV-2” turned out to be a successful one. Without AGBL Egypt support, it might not have been possible. In addition, I would like to thank all your respectable team for their dedication and the ultimate support as well.”
Dr Mohamed Abdel Hakim, a senior Area Manager at AGBL Egypt, emphasized, “The AGBL Egypt team has been working hard to make sure we support our partners in their diagnostic and research efforts to combat the virus. We take great pride in being part of the national effort to provide reliable and prompt testing for Egyptian citizens.”
-Ends-
About AGBL Egypt
AGBL Egypt is a member of the AGBL group of companies, the largest biomedical distribution group in the Middle East, Africa, and Asia region. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic centers in emerging healthcare markets. AGBL Egypt is headquartered in Cairo and covers Egypt and Sudan.
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
